173 related articles for article (PubMed ID: 29180031)
1. Will we have new pertussis vaccines?
Locht C
Vaccine; 2018 Aug; 36(36):5460-5469. PubMed ID: 29180031
[TBL] [Abstract][Full Text] [Related]
2. Pertussis: Where did we go wrong and what can we do about it?
Locht C
J Infect; 2016 Jul; 72 Suppl():S34-40. PubMed ID: 27161992
[TBL] [Abstract][Full Text] [Related]
3. Live pertussis vaccines: will they protect against carriage and spread of pertussis?
Locht C
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S96-S102. PubMed ID: 28341014
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.
Thorstensson R; Trollfors B; Al-Tawil N; Jahnmatz M; Bergström J; Ljungman M; Törner A; Wehlin L; Van Broekhoven A; Bosman F; Debrie AS; Mielcarek N; Locht C
PLoS One; 2014; 9(1):e83449. PubMed ID: 24421886
[TBL] [Abstract][Full Text] [Related]
5. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
[TBL] [Abstract][Full Text] [Related]
6. Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice.
Feunou PF; Kammoun H; Debrie AS; Locht C
Vaccine; 2014 Jul; 32(34):4281-8. PubMed ID: 24950361
[TBL] [Abstract][Full Text] [Related]
7. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
Mielcarek N; Debrie AS; Raze D; Bertout J; Rouanet C; Younes AB; Creusy C; Engle J; Goldman WE; Locht C
PLoS Pathog; 2006 Jul; 2(7):e65. PubMed ID: 16839199
[TBL] [Abstract][Full Text] [Related]
8. Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives.
Dubois V; Locht C
Front Immunol; 2021; 12():701285. PubMed ID: 34211481
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
10. Pertussis: acellular, whole-cell, new vaccines, what to choose?
Locht C
Expert Rev Vaccines; 2016 Jun; 15(6):671-3. PubMed ID: 26938372
[No Abstract] [Full Text] [Related]
11. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
12. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
[TBL] [Abstract][Full Text] [Related]
13. Acellular vaccines for preventing whooping cough in children.
Zhang L; Prietsch SO; Axelsson I; Halperin SA
Cochrane Database Syst Rev; 2011 Jan; (1):CD001478. PubMed ID: 21249646
[TBL] [Abstract][Full Text] [Related]
14. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
McIntyre PB; Turnbull FM; Egan AM; Burgess MA; Wolter JM; Schuerman LM
Vaccine; 2004 Dec; 23(3):380-5. PubMed ID: 15530684
[TBL] [Abstract][Full Text] [Related]
15. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route.
Li R; Lim A; Alonso S
Bioeng Bugs; 2011; 2(6):315-9. PubMed ID: 22067832
[TBL] [Abstract][Full Text] [Related]
16. New pertussis vaccination approaches: en route to protect newborns?
Locht C; Mielcarek N
FEMS Immunol Med Microbiol; 2012 Nov; 66(2):121-33. PubMed ID: 22574832
[TBL] [Abstract][Full Text] [Related]
17. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
18. Construction and evaluation of a pertactin-deficient live attenuated pertussis vaccine candidate BPZE1 derivative.
Solans L; Debrie AS; Coutte L; Locht C
Vaccine; 2021 May; 39(21):2843-2849. PubMed ID: 33896662
[TBL] [Abstract][Full Text] [Related]
19. Mucosal immunisation of murine neonates using whole cell and acellular Pertussis vaccines.
Hale C; Humphreys IR; Hussell T; Bowe F; Clare S; Pickard D; Preston A; Del Giudice G; Dougan G
Vaccine; 2004 Sep; 22(27-28):3595-602. PubMed ID: 15315838
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of two pertussis vaccines in preterm Danish children.
Hviid A
Vaccine; 2009 May; 27(23):3035-8. PubMed ID: 19428916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
